Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. A Low Cost Integrated Method for Isolation of M. Tuberculosis DNA from Raw Sputum

    SBC: AKONNI BIOSYSTEMS INC.            Topic: NIAID

    Nucleic acid testing offers the potential to improve tuberculosis diagnosis world wideHigh purity DNA is essential to the success of virtually any downstream nucleic acid detection methodWe propose to develop a sample preparation system to extract and purify Mycobacterium tuberculosis DNA from raw sputumThe project goalas described in the solicitationPHSTopicis to develop an inexpensive and easy t ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. TOPIC #355- SBIR PHASE II- A 3D PERFUSABLE PLATFORM FOR HTS ACROSS DIVERSE RACIAL/ETHNIC CANCER SPE

    SBC: MIMETAS US, INC            Topic: NCI

    Prostate cancerPCaincidence and mortality in African American men is two times greater than men of other races ethnicities in the United StatesElucidating the underlying mechanisms for this cancer health disparityCHDis critical to patient treatment and improved patient outcomehowever there are no in vitro models available to adequately recapitulate the PCa tumor microenvironment across races ethni ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. TOPIC #366- PHASE II SBIR CONTRACT- CLONOGENIC HIGH- THROUGHPUT ASSAY FOR SCREENING RADIATION MODULATION

    SBC: SuviCa, Inc.            Topic: NCI

    Clonogenic assays measure the ability of single cells to proliferate and form a colonyThis process approximates closely the regrowth and recurrence of tumors after treatment with radiation or chemotherapyproviding an assay to screen for drugs that block this processYetclonogenic assays are labor intensive and too cumbersome for high throughout screeningHTSof compound librariesHere we propose to de ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. TOPIC 368: TREATMENT OPTIMIZATION BY COMBINED A-EMITTER (ARPT)/RADIOTHERAPY (XRT) DOSIMETRY FOR PROSTATE CANCER PATIENTS

    SBC: RADIOPHARMACEUTICAL IMAGING AND DOSIMETRY, LLC            Topic: NCI

    We propose to demonstrate a cloud based software service for Combination alpha emitter radiopharmaceutical therapyRPTand external beam radiotherapyXRTCX RPTtreatment planningBoth modalities deliver radiationWe will demonstrate feasibility clinically by collecting the data needed from an existing Hopkins trial evaluating combination XRT with XofigoRa dichlorideanRPT that concentratesparticle radiat ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty

    SBC: Longeveron LLC            Topic: NIA

    Aging Frailty is a biologically driven geriatric syndrome of multisystem physiological decline that is distinct from normal aging and disproportionately increases vulnerability to adverse clinical outcomesFrailty has an overall prevalence ofof thoseyears and olderand there is growing awareness in the geriatric community to diagnose and treat this conditionas it is not an inevitable consequence of ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. TOPIC 345: PREDICTIVE BIOMARKERS OF PROSTATE CANCER PATIENT SENSITIVITY FOR RADIATION LATE EFFECTS

    SBC: Shuttle Pharmaceuticals, Inc.            Topic: NCI

    To address the goals of developing ""predictive biomarkers of adverse reactions to radiation treatment""we propose to perform a multi site analytic validation of the product""metabolite panel kit""developed in the Phase I SBIR effortResults of plasma metabolite analysis in defined cohorts of patients treated with SBRT for prostate cancer will be tested for precisionaccuracy and reproducibility in ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  8. A single dose long-acting non-addictive polymer conjugate formulation of buprenorphine that provides immediate and prolonged analgesia for post-operative pain

    SBC: SERINA THERAPEUTICS INC            Topic: NINDS

    PAProject Summary Abstract SERis a long acting polymer pro drug of buprenorphine that is being developed to treat postoperative pain following major surgeries such as bunionectomyabdominoplastythoracotomy and knee and hip surgerySERhas no biological activity by itselfbut when administered in vivo by subcutaneous injection it enters the vascular compartment where a plasma esterasebutyrylcholinester ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Functional integrated human-on-a-chip systems for Alzheimer's research

    SBC: Hesperos, Inc.            Topic: NIA

    Project SummaryThe goal of this proposalat the end of the Phase II effortis to have a service available to academia and industry to screen drugs for Alzheimer s to predict patient outcomes and determine how potential therapeutics are delivered to the CNSThere are currently few companies able to offer multi organ evaluation with a recirculating medium utilizing functional readoutsand none that addr ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. SBIR TOPIC 354: A NOVEL PREDICTIVE TEST FOR RESPONSE TO COMBINATION IMMUNOTHERAPIES FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)

    SBC: Biomarker Strategies, LLC            Topic: NCI

    In the proposed Phase II studywe will further develop our PathMAPImmunotherapy test to address an unmet clinical need within the NSCLC patient populationWe hope to create a test that is able to accurately predict clinical response to PDPD Ltargeted immune checkpoint inhibitors alone and in combination with chemotherapiesOur development work in Phase II will be based on our initial work performed i ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government